Myeloid Cells as Targets for Therapy in Solid Tumors

Tiziana Cotechini, Terry R. Medler, Lisa M. Coussens

Research output: Contribution to journalReview article

18 Scopus citations

Abstract

It is well established that cancer development ensues based on reciprocal interactions between genomically altered neoplastic cells and diverse populations of recruited "host" cells co-opted to support malignant progression. Among the host cells recruited into tumor microenvironments, several subtypes of myeloid cells, including macrophages, monocytes, dendritic cells, and granulocytes contribute to tumor development by providing tumor-promoting factors as well as a spectrum of molecules that suppress cytotoxic activities of T lymphocytes. Based on compelling preclinical data revealing that inhibition of critical myeloid-based programs leads to tumor suppression, novel immune-based therapies and approaches are now entering the clinic for evaluation. This review discusses mechanisms underlying protumorigenic programming of myeloid cells and discusses how targeting of these has potential to attenuate solid tumor progression via the induction and of mobilization CD8 + cytotoxic T cell immunity. ©

Original languageEnglish (US)
Pages (from-to)343-350
Number of pages8
JournalCancer Journal (United States)
Volume21
Issue number4
DOIs
StatePublished - Jul 5 2015

Keywords

  • B cell
  • CD8 + T cell
  • chemotherapy
  • dendritic cell
  • eosinophil
  • immunotherapy
  • lymphocyte
  • macrophage
  • myeloid
  • neutrophil
  • tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Myeloid Cells as Targets for Therapy in Solid Tumors'. Together they form a unique fingerprint.

  • Cite this